CClinicalTrials.gg
Not yet recruitingNCT07820969Updated Sep 15, 2026

Post-op Analgesia of Nail Unit Procedures

A Phase 4 interventional study of Suzetrigine and Oxycodone + Acetaminophen in Nail Diseases, sponsored by University of Miami. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by University of Miami · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to directly compare the efficacy of suzetrigine vs. oxycodone+acetaminophen vs. alternating acetaminophen/ibuprofen in controlling post-operative pain after the following nail unit procedures.

02

Conditions studied

  • Nail Diseases
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All patients age 18+ able to understand and provide written consent in English or Spanish who present to Dr. Brian Morrison's clinic at the University of Miami and are undergoing a nail unit procedure.

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 18 or adults unable to consent.
  • Patients who are pregnant or incarcerated.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Suzetrigine Group

    Participants in this arm will receive suzetrigine for 5 days for post-operative pain management following nail unit procedures.

    Drug: Suzetrigine

  • Active comparator
    Oxycodone + Acetaminophen Combination Group

    Participants in this arm will receive a combination of oxycodone and acetaminophen for 5 days for post-operative pain management following nail unit procedures.

    Drug: Oxycodone + Acetaminophen

  • Active comparator
    Alternating Acetaminophen/ibuprofen Group

    Participants in this arm will receive alternating acetaminophen and ibuprofen administered orally every 6 hours for 5 days starting the day of the nail procedure.

    Drug: Acetaminophen/Ibuprofen

Interventions

  • DrugSuzetrigine

    Participants will receive two 50 mg oral tablets on day 1, followed by 50 mg oral tablets every 12 hours for 5 days

  • DrugOxycodone + Acetaminophen

    Participants will receive Oxycodone + acetaminophen combination administered orally at a dose of 50 mg/325 mg per tablet, every 6 hours for 5 days starting the day of the nail procedure

  • DrugAcetaminophen/Ibuprofen

    Participants will receive Acetaminophen administered orally at a dose of 650 mg every 6 hours for 5 days starting the day of the nail procedure. Alternate with ibuprofen 400 mg every 6 hours for 5 days starting day of nail procedure

05

What researchers measure

Primary outcomes

  1. Change in Post-Operative Pain Intensity

    Pot-operative pain intensity measured using the Numeric Rating Scale (NRS, 0-10), where 0 indicates no pain and 10 indicates worst possible pain; higher scores indicate greater pain following nail unit procedures.

    Time frame: 24 hours post nail procedure, 48 hours post nail procedure, 72 hours post nail procedure

06

Study locations

1 site
  • University of Miami, Phillip Frost Dermatology Clinic
    Miami, Florida 33136, United States
    • Brian W Morrison, MD · Contact · bmorrison@med.miami.edu · 305-243-4472
    • Brian Morrison, MD · Principal investigator
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07820969
Lead sponsor
University of Miami
Responsible party
Brian W Morrison (Associate Professor of Clinical, University of Miami) — Principal investigator
First posted
Sep 15, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Brian W Morrison, MD
Contact
bmorrison@med.miami.edu
305-243-4472
Brian Morrison, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion